Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 20.1
edited by manuelmenendez
on 2025/01/28 00:03
Change comment: There is no comment for this version
To version 4.1
edited by manuelmenendez
on 2025/01/27 22:53
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for neurodegenerative diseases// =
5 += My Collab's Extended Title =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +My collab's subtitle
9 9  )))
10 10  )))
11 11  
... ... @@ -13,75 +13,18 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -== **Overview** ==
17 +* Notice how the table of contents on the right
18 +* is automatically updated
19 +* to hold this page's headers
19 19  
20 -The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on:
21 += Who has access? =
21 21  
22 -* **Axis 1**: Etiology (genetic or other causes of diseases).
23 -* **Axis 2**: Molecular Markers (biomarkers).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -
27 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
28 -
29 -
30 -This methodology enables:
31 -
32 -* Greater precision in diagnosis.
33 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
34 -* Stratification of patients for personalized treatment.
35 -
36 -== **Diagnostic Axes** ==
37 -
38 -* (((
39 -**Axis 1: Etiology**
40 -
41 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
42 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
43 -* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
23 +Describe the audience of this collab.
44 44  )))
45 -* (((
46 -**Axis 2: Molecular Markers**
47 47  
48 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
49 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
50 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
51 -)))
52 -* (((
53 -**Axis 3: Neuroanatomoclinical**
54 54  
55 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
56 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
57 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
58 -)))
59 -
60 -== **Applications** ==
61 -
62 -This system enhances:
63 -
64 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
65 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
66 -
67 -== Who has access? ==
68 -
69 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
70 -
71 -== How to Contribute ==
72 -
73 -* Access the `/docs` folder for guidelines.
74 -* Use `/code` for the latest AI pipelines.
75 -* Share feedback and ideas in the wiki discussion pages.
76 -
77 -== Key Objectives ==
78 -
79 -* Develop interpretable AI models for diagnosis and progression tracking.
80 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
81 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
82 -)))
83 -
84 -
85 85  (% class="col-xs-12 col-sm-4" %)
86 86  (((
87 87  {{box title="**Contents**"}}
... ... @@ -88,11 +88,6 @@
88 88  {{toc/}}
89 89  {{/box}}
90 90  
91 -== Main contents ==
92 -
93 -* `/docs`: Documentation and contribution guidelines.
94 -* `/code`: Machine learning pipelines and scripts.
95 -* `/data`: Sample datasets for testing.
96 -* `/outputs`: Generated models, visualizations, and reports.
33 +
97 97  )))
98 98  )))
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view